Updates in adjuvant therapy in pancreatic cancer: Gemcitabine and beyond

Journal of the Pancreas

Volumn 11, Issue 2, 2010, Pages 144-147

  Richter, Joshua ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Chemotherapy, adjuvant; Combined modality therapy; Erlotinib; Gemcitabine; Pancreatic neoplasms

Indexed keywords

ERLOTINIB; GEMCITABINE; GI 4000; UNCLASSIFIED DRUG;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ANEMIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DATA BASE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE MUTATION; HUMAN; INTESTINE OBSTRUCTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE RAS; PANCREAS CANCER; PATIENT COMPLIANCE; PATIENT SELECTION; PREDICTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; DEOXYCYTIDINE; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77749285628     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57. [PMID 15051286]
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77. [PMID 17227978]
4. Bao PQ, Ramanathan RK, Moser AJ, Bahary N, Lembersky BC, Bartlett DL, et al. Phase II trial of adjuvant gemcitabine and erlotinib for resected pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 224.
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677]
6. Richards DA, Muscarella P, Ritch PS, Fisher WE, Flynn PJ, Whiting SH, et al. A randomized phase II adjuvant trial of resected patients with ras mutation bearing pancreas cancer treated with GI-4000 and gemcitabine or gemcitabine alone: A safety analysis of the first 100 treated patients. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 229.
7. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, et al. k-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143:545-54. [PMID 8342602]
8. Subbiah S, Aldoss I, Gonsalves W, Tashi T, Al-Howaidi I, Silberstein PT. Adjuvant chemotherapy versus chemoradiation therapy in resectable pancreatic cancer: Retrospective analysis from the VA Central Cancer Registry (VACCR) database. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 230.
9. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230:776-82. [PMID 10615932]
10. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-10. [PMID 15028824]
11. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma V.1.2009. NCCN Clinical Practice Guidelines in Oncology.
12. Smith JK, Ng S, Simons JP, Zhou Z, Shah SA, McDade TP, et al. Adjuvant therapy for resectable pancreatic cancer: A simple prediction rule. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 236.
13. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008; 6:955-64. [PMID 19129927]
14. Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T, Ni X, Qin X. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 2009; 9:191. [PMID 19534821]
15. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP. J Pancreas (Online) 2007; 8:545-52. [PMID 17873458]